Hurel Corporation develops advanced artificial tissue constructs and microfluidic cell-based assay platforms. Those platforms are used by major pharmaceutical research organizations in pre-clinical drug development and for toxicological testing of industrial materials and consumer products. The company is led by CEO Robert Freedman and has locations in North Brunswick, New Jersey and Beverly Hills, California. Hurel intends to use capital to support the commercial launch of its current products. It also plans to fund research and development of its technologies and future products and to cover other general corporate purposes.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2013